Items tagged with Drug-resistant TB
Increased risk of death with MDR-TB (post)
Diptendu Bhattacharya and Ashna Ashesh, both multidrug-resistant TB (MDR-TB) survivors and associated with Survivors Against TB, highlight the enormous burden of drug-resistant TB in India and how best to deal with the challenges.
RESIST-TB November 2020 newsletter (post)
RESIST-TB released its November 2020 newsletter with the latest research publications on drug-resistant TB.
J&J can sell TB drug to minors after govt panel waives local trials (post)
New Delhi: A Government of India drugs advisory committee has approved the use of Johnson & Johnson’s (J&J) bedaquiline – used to treat tuberculosis (TB) – for minor patients in the country without conducting any local clinical trials first.
Patients in South Africa to access six-month, all-oral treatment for highly drug-resistant TB (post)
Pretoria, 10 December 2020 — TB Alliance welcomes the Wits Health Consortium and the South African National Department of Health (DoH)’s announcement of an initiative to provide a new, shorter treatment regimen for people affected with highly drug-resistant forms of tuberculosis (TB). Funded by the United States Agency for International Development, a new clinical access program (CAP) will enroll 400 people in South Africa for treatment with a three-drug, six-month, all-oral regimen of bedaquiline, pretomanid and linezolid (known as the BPaL regimen) that has been shown to demonstrate a favorable outcome in 90% of patients.1 This treatment was developed by TB Alliance and studied in its pivotal Nix-TB trial, which was also conducted in South Africa.
400 people in South Africa with highly drug-resistant TB to get new three-drug regimen (post)
Treatment of drug-resistant forms of tuberculosis (DR-TB) in South Africa has been transformed over the last decade. Most people with DR-TB no longer have to take daily injections and treatment is often completed in nine months, compared to 18 to 24 months in the past. Maybe most importantly, fewer people are dying of DR-TB and fewer people are suffering hearing loss, a common side effect of injections used in the past.
RESIST-TB January 2021 newsletter (post)
RESIST-TB released its January 2021 newsletter with the latest research publications on drug-resistant TB.
New TB drug regimen slashes treatment time (post)
Tuberculosis is an age-old respiratory scourge, with a new twist: growing resistance to multiple first- and second-line drugs. UF researchers and physicians report on using a novel treatment to slash treatment time — and cure — a patient with extensively drug-resistant TB.
Drug cocktail tested on extremely drug-resistant TB (post)
-- Tajikistan becomes the second country in the world to try out the BPaL regimen
-- WHO recommends the novel treatment under operational research conditions
-- New drug regimen is easy to use and more affordable
The rise of multidrug-resistant TB in HIV patients (post)
Multidrug-resistant tuberculosis (MDR-TB) was declared a public health crisis by the World Health Organization (WHO) in 2013 and each year continues to pose a serious threat to millions, especially to those infected with HIV. TB is one of the top 10 causes of death worldwide, and 15% of HIV-associated tuberculosis (TB) deaths were caused by MDR-TB in 2018. Furthermore, HIV patients are 20 times more likely to develop active TB than those without HIV.
Page 67 of 117 · Total posts: 0
←First 66 67 68 Last→